modelDesonide
Extends from Pharmacolibrary.Drugs.ATC.S.S01BA11.
Information
| name: | Desonide | |
| ATC code: | S01BA11 | route: | topical |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 1 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
Desonide is a low-potency topical corticosteroid used for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as eczema and dermatitis. It is usually applied as a cream, ointment, gel, or lotion to the skin. Desonide is approved for use in many countries and remains commonly used, particularly in pediatric and sensitive skin populations due to its favorable safety profile.
Pharmacokinetics
No published human pharmacokinetic (PK) models or systemic PK parameter values for desonide topical formulations were identified in the literature. Estimates in this record are inferred from general corticosteroid percutaneous absorption and expected PK properties.
References
Sun, Y, et al., & Yang, G (2024). Evaluation of Bioequivalence and Pharmacokinetic Profiles for Topical Desonide Cream Using Chinese Skins. Skin pharmacology and physiology 37(4-6) 70–79. DOI:10.1159/000540782 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39159613
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)